The National Institute for Health and Care Excellence (NICE) has expressed increasing willingness to reimburse innovative products with high uncertainty under Managed Access Agreements (MSUs), while additional data is being collected on the new Cancer Drugs Fund (CDF) or Highly Specialized Technologies (HST). This research aimed to review the data collection rules of current MMA. The new approach allows for earlier access to treatment. Nice`s assessment process now starts much earlier so that the final guidelines can be published shortly after the receipt of a medicine`s marketing authorisation. If you need more information about the SFAO, please email the Cancer Drugs Fund team. Use in combination with paclitaxel nab in the treatment of adult patients with triple-negative inoperable local or metastatic breast cancer (TNBC) whose tumors have PD-L1 expression >1% and have not received prior chemotherapy for metastatic disease in accordance with NICE TA639. • On behalf of the NHSE from 31 July 2020, interim funding through the CDF will be made available until that date. • Patients who started this indication through the MHRA Early Access to Medicines Scheme (EAMS) and who do not meet the new criteria should continue to receive the medicine from the manufacturer. We checked all current MMA between NHS England and manufacturers as of 29 October 2018 and extracted important data. Atezolizumab plus bevacizumab is recommended in the CDF as an option for the treatment of advanced or inoperable hepatocellular cancer (HCC) in adults, who have not received prior systemic therapy unless: • they have Child-Pugh Grade A liver failure and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 This indication was previously available through the EAMS regimen.
. . .